Findings

What do systematic reviews say?

6 questions · 6 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 33.3%GRADE not reported 0 · 0%Very low 0 · 0%Low 4 · 66.7%Moderate 0 · 0%High 0 · 0%

Low dose naldemedine vs higher dose

Symptoms of opioid withdrawal in the medium term · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction

Low dose naldemedine showed no clear difference in symptoms of opioid withdrawalfin the medium termb compared with higher doses (low certainty).

1 finding from 1 review

Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 112 participants
Low

Low dose naldemedine vs higher dose

Serious adverse eventsg · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction

Low dose naldemedine showed no clear difference in serious adverse eventsg compared with higher doses (low certainty).

1 finding from 1 review

Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care 2022 · Cochrane Headline outcomes only
RR 0.25 [0.03, 2.17]
1 study · 112 participants
Low

Low dose naldemedine vs higher dose

Adverse events · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction

Low dose naldemedine showed no clear difference in adverse events compared with higher doses (low certainty).

1 finding from 1 review

Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care 2022 · Cochrane Headline outcomes only
RR 0.84 [0.67, 1.06]
1 study · 112 participants
Low

Low dose naldemedine vs higher dose

Laxation response: risk of spontaneous rescue‐free bowel movements in the short terma · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction

The review found no eligible studies for this question.

1 finding from 1 review

Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Low dose naldemedine vs higher dose

Laxation response: risk of spontaneous rescue‐free bowel movements in the medium termb · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction

Low dose naldemedine may leads to lower laxation response: risk of spontaneous rescue‐free bowel movements… compared with higher doses (low certainty).

1 finding from 1 review

Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care 2022 · Cochrane Headline outcomes only
RR 0.69 [0.53, 0.89]
1 study · 111 participants
Low

Low dose naldemedine vs higher dose

Laxation response: patient assessment of change in bowel status at the end of trial · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction

The review found no eligible studies for this question.

1 finding from 1 review

Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found